What is the translation of " MULTICENTER STUDY " in Slovenian?

• multicentrična študija
• multicentrični študiji

Examples of using Multicenter study in English and their translations into Slovenian

The safety of subcutaneous tocilizumab in RA includes a double-blind, controlled, multicenter study, SC-I.
Varnost uporabe subkutanega tocilizumaba pri zdravljenju revmatoidnega artritisa vključuje dvojno slepo, kontrolirano, multicentrično študijo SC-I.

Study 2 was a randomized, controlled, multicenter study comparing the Zevalin therapeutic regimen to treatment with rituximab.
Druga študija je bila randomizirana, kontrolirana, multicentrična študija, v kateri so primerjali terapevtsko shemo zdravljenja z Zevalinom z rituksimabom.

Cayston was compared to TNS over three 28-day courses of treatment in a randomised, active- controlled, multicenter study(GS-US-205-0110).
Zdravilo Cayston so primerjali z RTN v treh 28-dnevnih ciklih zdravljenja v randomizirani, aktivno kontrolirani multricentrični študiji(GS-US-205-0110).

An open-label, randomised, non-comparative multicenter study was conducted in patients who failed initial treatment with 400 or 600 mg imatinib.
Odprta, randomizirana, neprimerjalna, multicentrična študija je bila izvedena pri bolnikih, pri katerih je bilo začetno zdravljenje z imatinibom v odmerku 400 mg ali 600 mg neuspešno.

The radiographic response of subcutaneous administered tocilizumab was assessed in a double-blind, controlled, multicenter study in patients with active RA(SC-II).
V dvojno slepi, kontrolirani, multicentrični študiji pri bolnikih z aktivnim revmatoidnim artritisom(SC-II) so radiološko ocenjevali subkutano dani tocilizumab.

Study 2 was a randomized, controlled, multicenter study comparing the Zevalin therapeutic regimen versus treatment with rituximab.
Druga študija je bila randomizirana, kontrolirana, multicentrična študija, v kateri so terapevtsko shemo zdravljenja z zdravilom Zevalin primerjali z zdravljenjem z rituksimabom.

The efficacy and safety of brentuximab vedotin as a single agent was evaluated in an open-label, single-arm, multicenter study in 58 patients with relapsed or refractory sALCL.
Učinkovitost in varnost brentuksimaba vedotina kot edinega zdravila so ocenili v odprti, multicentrični študiji z enim krakom pri 58 bolnikih s ponovljenim ali z refraktarnim sALCL.

An open-label, single-arm, multicenter study was conducted in patients with lymphoid blast phase CML or Ph+ ALL who were resistant or intolerant to prior imatinib therapy.
Pri bolnikih s KML v obdobju limfoblastne preobrazbe ali s Ph+ALL, ki imatiniba niso prenašali ali pa so bili na predhodno zdravljenje z imatinibom odporni, je bila izvedena odprta, enoskupinska(“ single- arm”), multicentrična študija.

The immunogenicity of Prevenar has been investigated in an open-label, multicenter study in 49 infants with sickle cell disease.
Imunogenost cepiva Prevenar so raziskali v odprti multicentrični študiji pri 49 dojenčkih z anemijo srpastih celic.

MONDAY, Aug. 29, 2016(HealthDay News)-- Three already existing drugs may offer pregnant women and their developing fetuses protection against the damaging effects of Zika virus, a new multicenter study reports.
PONEDELJEK, 2016(HealthDay News)- Tri že obstoječe droge lahko nosečim ženskam in njihovemu razvoju plodov zagotovijo zaščito pred škodljivimi učinki virusa Zika, novega multicentričnega poročila o študijah.

Voriconazole was compared to itraconazole as primary prophylaxis in an open-label, comparative, multicenter study of adult and adolescent allogeneic HSCT recipients without prior proven or probable IFI.
V odprti primerjalni multicentrični študiji so primerjali vorikonazol in itrakonazol kot primarno profilakso pri odraslih in mladostnikih, ki so bili prejemniki homolognih HSCT brez predhodno dokazane ali verjetne IGO.

An open-label, single-arm, multicenter study was conducted in patients resistant or intolerant to imatinib(i. e. patients who experienced significant toxicity during treatment with imatinib that precluded further treatment).
Ki so bili odporni na imatinib ali ga niso prenašali(to je pri bolnikih, pri katerih se je med zdravljenjem z imatinibom pojavila znatnejša toksičnost, ki je preprečila nadaljnje zdravljenje), je bila izvedena odprta, enoskupinska(“ single- arm”), multicentrična študija.

The efficacy and safety of brentuximab vedotin as a single agent was evaluated in a pivotal open-label, single-arm, multicenter study in 102 patients with relapsed or refractory HL.
Učinkovitost in varnost brentuksimaba vedotina kot edinega zdravila so ocenili v ključni, odprti, multicentrični študiji z enim krakom pri 102 bolnikih s ponovljenim ali z refraktarnim HL.

The safety and efficacy of Humira was assessed in an open-label, multicenter study in 32 children(2-< 4 years old or aged 4 and above weighing< 15 kg) with moderately to severely active polyarticular JIA.
Varnost in učinkovitost zdravila Humira so ocenili v odprti, multicentrični študiji pri 32 otrocih(starih od 2 do< 4 leta ali starih 4 leta ali več in s telesno maso< 15 kg) z zmernim do zelo aktivnim poliartikularnim JIA.

The therapeutic equivalence of once weekly alendronate 70 mg(n=519) and alendronate 10 mg daily(n=370) was demonstrated in a one-year, double-blind, multicenter study of postmenopausal women with osteoporosis.
Terapevtsko ekvivalenco alendronata 70 mg enkrat tedensko(n= 519) in alendronata 10 mg enkrat dnevno(n= 370) so dokazali v enoletni multicentrični študiji pri ženskah s pomenopavzalno osteoporozo.

In another study, of more than 1,000 recovering heart patients, performed at the Multicenter Study of Myocardial Ischemia in New Orleans, those who were not taking aspirin were three times more likely to have a fatal heart attack than those who were on the drug.
V drugi študiji, več kot 1.000 okreva srčne bolnike, ki se izvaja na Multicenter Študiji Miokardnega Ischemia v New Orleansu, tistih, ki niso bili z jemanjem aspirina so trikrat bolj verjetno, da imajo usoden srčni infarkt kot tisti, ki so bili na drog.

The safety and efficacy in the perioperative setting was evaluated in a phase 3 prospective, open-label, uncontrolled, multicenter study in male PTPs with severe and moderately severe haemophilia B using RIXUBIS.
Varnost in učinkovitost v perioperativnem okolju so ocenili v prospektivni, nezaslepljeni, nekontrolirani, multicentrični študiji zdravila RIXUBIS v 3. fazi pri preiskovancih moškega spola s hudo ali zmerno hemofilijo B, ki so že bili zdravljeni.

In an open-label, comparative, multicenter study comparing voriconazole and itraconazole as primary prophylaxis in adult and adolescent allogeneic HSCT recipients without prior proven or probable IFI, permanent discontinuation of voriconazole due to AEs was reported in 39.3% of subjects versus 39.6% of subjects in the itraconazole arm.
V odprti primerjalni multicentrični študiji, v kateri so primerjali vorikonazol in itrakonazol kot primarno profilakso pri odraslih in mladostnikih, ki so bili prejemniki homolognih HSCT brez predhodno dokazane ali verjetne IGO, so o trajni prekinitvi zdravljenja z vorikonazolom zaradi neželenih učinkov poročali pri 39,3% preiskovancev v primerjavi z 39,6% preiskovancev v skupini, ki je prejemala itrakonazol.

Voriconazole was investigated as secondary prophylaxis in an open-label, non-comparative, multicenter study of adult allogeneic HSCT recipients with prior proven or probable IFI.
Sekundarna profilaksa IGO- učinkovitost pri prejemnikih HSCT s predhodno dokazano ali verjetno IGO V odprti neprimerjalni multicentrični študiji pri odraslih prejemnikih homolognih HSCT s predhodno dokazano ali verjetno IGO, so vorikonazol raziskovali kot sekundarno profilakso.

In one of these trials, a randomized, multicenter study, 882 infants were assigned in a 3:1 ratio to receive either PROCOMVAX or Merck Haemophilus b Conjugate Vaccine(Meningococcal Protein Conjugate)(Merck PRP-OMPC Vaccine) plus Merck Hepatitis B(Recombinant) Vaccine at 2, 4, and 12-15 months of age, with the children monitored daily for five days after each injection for local reactions and systemic complaints.
V eni od teh raziskav, ki je bila randomizirana in multicentrična, so 882 dojenčkov v razmerju 3:1 razvrstili tako, da so prejemali PROCOMVAX ali pa Merckovo konjugirano cepivo proti hemofilusu b(meningokokni beljakovinski konjugat)(cepivo Merck PRP- OMPC) in Merckovo(rekombinantno) cepivo proti hepatitisu B. Otroke so cepili v starosti 2., 4. in od 12. do 15. meseca in jih glede lokalnih reakcij in sistemskih težav spremljali pet dni po vsaki injekciji.

The safety of NUEDEXTA was investigated in a double-blind, randomized, placebo-controlled, multicenter study over 12 weeks in 326 PBA patients with underlying ALS(60%) or MS(40%) and in a follow-up open-label extension phase with a patient subgroup of this study(253 patients) for an additional 84 days.
Varnost zdravila NUEDEXTA so proučevali v 12-tedenski dvojno slepi, randomizirani, s placebom nadzorovani, multicentrični študiji pri 326 bolnikih s PBP in osnovno boleznijo ALS(60%) ali MS(40%) ter sledilni odprti podaljšani fazi s podskupino bolnikov v tej študiji(253 bolnikov), ki je trajala dodatnih 84 dni.

His main area of research is novel therapies in bleeding disorders in which he has served as Principal Investigator for over 70 international multicenter studies.
Njegovo glavno področje raziskav so nove terapije pri motnjah krvavitve, pri katerih je bil glavni preiskovalec za več kot 70 mednarodnih večcentričnih študij.

The efficacy and safety of MabThera in alleviating the symptoms and signs of rheumatoid arthritis was demonstrated in three randomized, controlled, double-blind, multicenter studies.
Učinkovitost in varnost zdravila MabThera v lajšanju simptomov in znakov revmatoidnega artritisa sta bili dokazani v treh randomiziranih, kontroliranih, dvojno slepih, multicentričnih študijah.

Efficacy in Pediatric Studies Ertapenem was evaluated primarily for pediatric safety and secondarily for efficacy in randomized comparative, multicenter studies in patients 3 months to 17 years of age.
Učinkovitost v pediatričnih raziskavah Ertapenem so ocenjevali primarno z namenom presoje pediatrične varnosti in sekundarno z namenom presoje učinkovitosti v randomiziranih, primerjalnih, multicentričnih raziskavah pri pediatričnih bolnikih, starih od 3 mesece do 17 let.

The safety and efficacy of axitinib were evaluated in a randomised, open-label, multicenter Phase 3 study.
Varnost in učinkovitost aksitiniba so ocenjevali v randomizirani, odprti, multicentrični študiji faze 3.

The Allopurinol and Placebo-Controlled Efficacy Study of Febuxostat(APEX) was a Phase 3, randomized, double-blind, multicenter, 28-week study.
Z alopurinolom in s placebom kontrolirana študija učinkovitosti febuksostata(Allopurinoland Placebo- Controlled Efficacy Studyof Febuxostat- APEX) je bila randomizirana, dvojno slepa, multicentrična, 28- tedenska študija 3. faze.

This was an open-label, multicenter, single-arm study of idursulfase infusions in male Hunter syndrome patients between the age of 16 months and 7.5 years.
To je bila odprta, multicentrična študija z enim krakom, v kateri so ocenjevali infuzijo idursulfaze pri bolnikih moškega spola s Hunterjevim sindromom, starih od 16 mesecev do 7,5 leta.

Study 02507 was a randomized, double-blind, placebo-controlled, multicenter clinical study in 40 patients with GD1.
Študija 02507 je bila randomizirana, dvojno slepa, s placebom nadzorovana, multicentrična klinična študija pri 40 bolnikih z GD1.

Study 02607 was a randomized, open-label, active-controlled, non-inferiority, multicenter clinical study in 159 patients previously stabilised with ERT.
Študija 02607 je bila randomizirana, odprta, z aktivno učinkovino nadzorovana, multicentrična klinična študija enakovrednih skupin pri 159 bolnikih, ki so predhodno dosegli stabilno stanje z nadomestnim encimskim zdravljenjem(ERT).

FACT Study: The Febuxostat Allopurinol Controlled Trial(FACT) Study was a Phase 3, randomized, double-blind, multicenter, 52-week study.
Študija FACT: Z alopurinolom kontrolirana študija s febuksostatom(Febuxostat Allopurinol Controlled Trial- FACT) je bila randomizirana, dvojno slepa, multicentrična, 52-tedenska študija 3. faze.